← Leaderboards
Georgia Zarkada
Yale University
$965,765
Attributed
$965,765
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $288K · FY2018–25$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$965,765 · 2
By mechanism
R00$771,759 · 1
K99$194,006 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Michael Simons$49,269,368
- Anne Christine Eichmann$13,173,934
- Alan Ross Morrison$5,386,740
- Stephen M Strittmatter$76,187,371
- Naftali Kaminski$42,947,928
Others in their field
Other Emerging Leaders on “Eye Diseases”
- Yunda Huang · Fred Hutchinson Cancer Center$15,930,485
- Ionut Bebu · George Washington University$14,731,026
- Barbara Halina Braffett · George Washington University$14,731,026
- Kristen Jacklin · University Of Minnesota$11,691,156
- Ruchira Singh · University Of Rochester$7,017,017
- Anthony J St Leger · University Of Pittsburgh At Pittsburgh$6,355,531
Research focus
Eye DiseasesGene TargetingAblationExperimental StudyGene ExpressionFutureAge Related Macular DegenerationBiologyAngiogenesisBlood VesselsAffectCell BehaviorCell MaturationCell ProliferationAwardCellular BiologyChoroidal NeovascularizationComparativeBlindnessDefectDiabetic RetinopathyEndothelial CellsCardiovascular SystemGenetic
Grant awards (5)
Targeting TGFB signaling to treat ocular neovascular disease$239,508
R00 · FY2025 · EY · contact PI
Targeting TGFB signaling to treat ocular neovascular disease$244,211
R00 · FY2024 · EY · contact PI
Targeting TGFB signaling to treat ocular neovascular disease$288,040
R00 · FY2023 · EY · contact PI
Targeting TGFB signaling to treat ocular neovascular disease$97,273
K99 · FY2019 · EY · contact PI
Targeting TGFB signaling to treat ocular neovascular disease$96,733
K99 · FY2018 · EY · contact PI